Reviewer's report

**Title:** Safety and Effectiveness of Adalimumab in a Clinical Setting that Reflects Canadian Standard of Care for the Treatment of Rheumatoid Arthritis (RA): Results from the CanAct Study

**Version:** 1  **Date:** 24 July 2011

**Reviewer:** Rudolf Puchner

**Reviewer's report:**

This large observational study reflects the efficacy of Biologics under conditions of routine clinical care. The data approve the already well investigated effectiveness and tolerability of adalimumab in real world clinical practice. It is of interest and comforting to know that the safety profile of adalimumab is similar to previously published trials. The reported low rate of serious infections is a matter of concern but should be further investigated over a longer period. Due to the large number of patients the study is of interest for practising rheumatologists.

In this study the vast majority of patients was first treated with a biologic agent after a long period of illness-the mean disease duration since diagnosis was 12.5 years (27.5% of patients that received prior BDMARD therapy included). It would be of interest to comment on this point.

**Level of interest:** An article whose findings are important to those with closely related research interests

**Quality of written English:** Acceptable

**Statistical review:** No, the manuscript does not need to be seen by a statistician.

**Declaration of competing interests:**

I have received honoraria from Abbott, BMS, Roche and Wyeth-Pfizer for speaking or research support